This week, researchers dismantle glaucoma disparities, diets rich in fatty fish may stave off AMD and new nasal sprays infuse the pharma pipeline with promise. Source: AAO
Investigators evaluated the safety and efficacy of the CyPass supraciliary microstent in patients with refractory open-angle glaucoma. Source: AAO
The paper describes the clinical features of patients with myelin oligodendrocyte glycoprotein antibodies (MOG-Ab), and explores the prognostic values of MOG autoimmunity. Source: AAO
In this retrospective, matched case-controlled study, researchers assessed outcomes after cataract surgery in patients who were undergoing treatment for neovascular AMD (nAMD). Source: AAO
This week, guppies give rival fish the stink eye, an Iowa clinic puts the IDx-DR screening tool to use and an experimental therapy for Stargardt disease receives an orphan drug designation in Europe. Source: AAO
Novartis has announced plans to spin off Alcon into a separately traded, stand-alone company. Source: AAO
This experimental study compared 2 techniques of preservation and transportation of Descemet membrane endothelial keratoplasty (DMEK) grafts. Source: AAO
An experimental treatment for proliferative diabetic retinopathy, emixustat hydrochloride, has shown promise in a phase 2 trial, according to a press release by Acucela. Source: AAO
This study by Douglas D. Koch and colleagues examined the effect of anterior chamber depth on the accuracy of 8 IOL formulas in patients with normal axial lengths. Source: AAO
This paper describes the presentation and outcomes of patients who developed endophthalmitis after intravitreal injection with VEGF inhibitors. Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »
